Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 38: 108-113, 1992;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tredger, J. M.
Right arrow Articles by Williams, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tredger, J. M.
Right arrow Articles by Williams, R.

Clinical Chemistry, Vol 38, 108-113, Copyright © 1992 by American Association for Clinical Chemistry

Monitoring cyclosporine in liver-transplant recipients: effects of clinical status on the performance of two monoclonal antibody-based methods

JM Tredger, CE Gonde and R Williams
Institute of Liver Studies, King's College Hospital, Denmark Hill, London, U.K.

The characteristics of the Abbott selective fluorescence polarization immunoassay for cyclosporine in whole blood (TDXSP) were compared with the Incstar radioimmunoassay by using kit standards (INCSP) or TDXSP standards (INCTDX) with samples from adult (48) and pediatric (24) liver-transplant recipients and a further 32 control specimens. The TDXSP assay was faster, less labor intensive, and more precise at higher concentrations; it gave results a median of 5 micrograms/L lower than INCSP values, irrespective of biliary T-tube status, patient's age, or severity of cholestasis in nine patients, comparisons being made for serum bilirubin more than eight times normal or less than 50 mumol/L. However, both assays overestimated INCTDX values by approximately 10%. There was a progressive increase in the ratio of TDXSP to both INCSP and INCTDX results in 57 samples stratified in relation to serum bilirubin concentrations. Cross-reactivity of TDXSP with cyclosporine metabolites M1 (23%) or M17 (12%) was greater than for INCSP (15% and 5%, respectively) or INCTDX (22% and 4%, respectively), but the converse was true with M21 (2% for TDXSP vs 4% and 8%, respectively). Some overestimation of cyclosporine whole-blood concentrations (relative to INCTDX results) may be detected with either the TDXSP (because of cross-reactivity with metabolites) or the INCSP assays (probably because of matrix effects). The similar magnitude of these overestimations suggests that alternative factors such as speed, precision, and cost may influence which method one selects for use in routine monitoring.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
A. R. Terrell, T. M. Daly, K. G. Hock, D. C. Kilgore, T. Q. Wei, S. Hernandez, D. Weibe, L. Fields, L. M. Shaw, and M. G. Scott
Evaluation of a No-Pretreatment Cyclosporin A Assay on the Dade Behring Dimension RxL Clinical Chemistry Analyzer
Clin. Chem., July 1, 2002; 48(7): 1059 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
W. Steimer
Performance and Specificity of Monoclonal Immunoassays for Cyclosporine Monitoring: How Specific Is Specific?
Clin. Chem., March 1, 1999; 45(3): 371 - 381.
[Abstract] [Full Text] [PDF]

Home page
 ANGIOLOGYHome page
G. Khoschsorur, T. Auer, G. Lanzer, P. Petritsch, H. Holzer, and K.H. Tscheliessnigg
The Determination of Metabolite M 17 and Its Meaning for Immunosuppressive Cyclosporin Therapy
Angiology, April 1, 1998; 49(4): 307 - 314.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Association for Clinical Chemistry.